Peanut OIT Phase 3 Trial Results Show Therapy Effective for Ages 4-55
Aimmune plans to submit a Biologics License Application for AR101 to the FDA by the end of 2018.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
